Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Small Molecules

Baylor College of Medicine to Present eFFECTOR Therapeutic-Driven Preclinical Data to Support the Development of Zotatifin in Triple Negative Breast Cancer at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer…

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem cell signaling pathways • Induces beneficial changes in the tumor microenvironment by increasing the production of proteins involved in…